LYL273 for Patients With Relapsed or Refractory mCRC
Colorectal Cancer
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
- +4.1
4 insiders sold shares within a month
Since Aug 21, 2026 · was worth 10, fading over time
Score over time
- Stage
- Phase 1/2
- Patients
- 155 (planned)
- Started
- Aug 1, 2022
- Main results expected
- Jun 2028
- Fully finished
- Jun 2032
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Phase 1: Incidence of adverse events (AEs) defined as dose-limiting toxicities (DLTs) during 3+3 dose escalation study
Measured over: Infusion (Day 0) to Day 28
Phase 1: Maximum tolerable dose (MTD) based on incidence of dose-limiting toxicities (DLTs) during 3+3 dose escalation study
Measured over: Infusion (Day 0) to Day 28
Phase 1: Recommended Phase 2 dose (RP2D) based on incidence of dose-limiting toxicities (DLTs) during 3+3 dose escalation study
Measured over: Infusion (Day 0) to Day 28
Phase 2: Estimate the efficacy of LYL273, as measured by overall response rate (ORR) based on Independent Review Committee (IRC) assessment per Response Evaluation Criteria in Solid Tumors RECIST Version 1.1 criteria
Measured over: Baseline to Month 18
Changes Tremor has spotted
Show details (technical version)
Score inputs
- insider_selling_cluster: base 10, now 4.1, since 2026-08-21, fades (half-life)
Raw record changes
- none yet
Trial ID NCT05319314 · record last updated 2026-10-30 · checked 2026-11-09 15:47 UTC